Studies suggest its use with chemotherapy as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and monotherapy for PD-L1-positive HNSCC (28). Here, CD274 is linked to head and neck squamous cell carcinoma.